No correlation between COMT genotype and entacapone benefi ts in Parkinson’s disease
- Author:
Ji Seon Kim
;
Ji-Young Kim
;
Jong-Min Kim
;
Jae Woo Kim
;
Sun Ju Chung Sung
;
R Kim RN
;
Mi J. Kim
;
Hee-Tae Kim
;
Kyoung-Gyu Choi
;
Dong-Ick Shin
;
Young Hee Sung
;
Kwang-Soo Lee
;
Han-Joon Kim
;
Jinwhan Cho
;
Mee Young Park
;
Hyun-Young Park
;
SeongMin Choi
;
Kun-Woo Park
;
Ho-Won Lee
;
Tae-Beom Ahn
;
Oh Dae Kwon
;
Sang-Jin Kim
;
Beom S Jeon
- Publication Type:Journal Article
- From:Neurology Asia
2011;16(3):211-216
- CountryMalaysia
- Language:English
-
Abstract:
Catechol-O-methyltransferase (COMT) inhibitors are used to increase the bioavailability of therapeutic
L-dopa. We examined the effi cacy of entacapone in Parkinson’s disease patients who had daily “off”
duration of ≤2 hours, and carried different COMT polymorphisms. A total of 168 PD patients were
recruited from 19 centers. Subjects were administered with 100–200 mg of entacapone in combination
with each dose of L-dopa for 2 months. The clinical effi cacy was evaluated based on the activities
of daily living (ADL), score on the Unifi ed Parkinson’s Disease Rating Scale (UPDRS), Hoehn and
Yahr (H&Y) stage, and Clinical Global Impression (CGI). COMT polymorphisms were genotyped.
3-O-methyldopa (3-OMD) levels were measured before and after the administration of entacapone.
Entacapone administration produced signifi cant improvements in the total daily “on” duration, ADL,
UPDRS score, and H&Y stage. Nineteen patients (11.3%) had the low-activity COMT genotype,
68 patients (40.5%) had the intermediate-activity COMT genotype, and 81patients (48.2%) had the
high-activity COMT genotype. The effi cacy, and adverse effects of entacapone therapy did not differ
between the three groups. There was a signifi cant reduction in 3-OMD, but this did not differ among
the three genotypes. Entacapone provided an increased “on” duration and improved motor function
in all COMT genotypes.
- Full text:P020150806591992044313.pdf
